Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1526 ARTÍCULOS , VIENDO DEL 1246 AL 1260

How plausible is an Alzheimer's disease vaccine?

Cacabelos R.

Expert Opin Drug Discov. 2020 Jan;15(1):1-6. doi: 10.1080/17460441.2019.1667329. Epub 2019 Sep 17.

Comparative pharmacokinetic study of the components in Alpinia oxyphylla Miq.-Schisandra chinensis (Turcz.) Baill. herb pair and its single herb between normal and Alzheimer's disease rats by UPLC-MS/MS

Qi Y, Cheng X, Jing H, Yan T, Xiao F, Wu B, Bi K, Jia Y.

J Pharm Biomed Anal. 2020 Jan 5;177:112874. doi: 10.1016/j.jpba.2019.112874. Epub 2019 Sep 12.

Mitochondrial calcium uniporter as a potential therapeutic strategy for Alzheimer's disease

Venugopal A, Iyer M, Balasubramanian V, Vellingiri B.

Acta Neuropsychiatr. 2020 Apr;32(2):65-71. doi: 10.1017/neu.2019.39. Epub 2019 Dec 26.

Circadian regulation of astrocyte function: implications for Alzheimer's disease

McKee CA, Lananna BV, Musiek ES.

Cell Mol Life Sci. 2020 Mar;77(6):1049-1058. doi: 10.1007/s00018-019-03314-y. Epub 2019 Sep 27.

How does a researcher choose the best rodent model for their Alzheimer's disease drug discovery study?

Van Dam D, De Deyn PP.

Expert Opin Drug Discov. 2020 Mar;15(3):269-271. doi: 10.1080/17460441.2020.1676719. Epub 2019 Oct 8.

Extracorporeal apheresis therapy for Alzheimer disease-targeting lipids, stress, and inflammation

Bornstein SR, Voit-Bak K, Rosenthal P, Tselmin S, Julius U, Schatz U, Boehm BO, Thuret S, Kempermann G, Reichmann H, Chrousos GP, Licinio J, Wong ML, Schally AV, Straube R.

Mol Psychiatry. 2020 Feb;25(2):275-282. doi: 10.1038/s41380-019-0542-x. Epub 2019 Oct 8.

Synaptic Copper, Amyloid-β, and Neurotransmitters in Alzheimer's Disease

Nam E, Nam G, Lim MH.

Biochemistry. 2020 Jan 14;59(1):15-17. doi: 10.1021/acs.biochem.9b00775. Epub 2019 Oct 11.

Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective

Derry PJ, Hegde ML, Jackson GR, Kayed R, Tour JM, Tsai AL, Kent TA.

Prog Neurobiol. 2020 Jan;184:101716. doi: 10.1016/j.pneurobio.2019.101716. Epub 2019 Oct 8.

Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD

Dyer AH, Murphy C, Lawlor B, Kennelly SP; NILVAD Study Group.

J Am Med Dir Assoc. 2020 Feb;21(2):194-200. doi: 10.1016/j.jamda.2019.08.006. Epub 2019 Oct 8.

Advanced analytical methodologies in Alzheimer's disease drug discovery

De Simone A, Naldi M, Tedesco D, Bartolini M, Davani L, Andrisano V.

J Pharm Biomed Anal. 2020 Jan 30;178:112899. doi: 10.1016/j.jpba.2019.112899. Epub 2019 Sep 29.

Granulovacuolar degeneration bodies: red alert for neurons with MAPT/tau pathology

Wiersma VI, Scheper W.

Autophagy. 2020 Jan;16(1):173-175. doi: 10.1080/15548627.2019.1680217. Epub 2019 Oct 23.

Assessment of evidence for or against contributions of Chlamydia pneumoniae infections to Alzheimer's disease etiology

Woods JJ, Skelding KA, Martin KL, Aryal R, Sontag E, Johnstone DM, Horvat JC, Hansbro PM, Milward EA.

Brain Behav Immun. 2020 Jan;83:22-32. doi: 10.1016/j.bbi.2019.10.014. Epub 2019 Oct 15.

Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease

Vander Zanden CM, Chi EY.

J Pharm Sci. 2020 Jan;109(1):68-73. doi: 10.1016/j.xphs.2019.10.024. Epub 2019 Oct 21.

The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer's disease

Webers A, Heneka MT, Gleeson PA.

Immunol Cell Biol. 2020 Jan;98(1):28-41. doi: 10.1111/imcb.12301. Epub 2019 Nov 20.

Considerations for future tau-targeted therapeutics: can they deliver?

Noble W, Jimenez-Sanchez M, Perez-Nievas BG, Hanger DP.

Expert Opin Drug Discov. 2020 Mar;15(3):265-267. doi: 10.1080/17460441.2020.1685977. Epub 2019 Oct 29.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias